An Observational Study on Lignocaine Infusion for Intractable Chronic Pain by Aslam, Amir et al.
Article
An Observational Study on Lignocaine Infusion 
for Intractable Chronic Pain
Aslam, Amir, Singh, Jaipaul and Rajbhandari, Satyan
Available at http://clok.uclan.ac.uk/36335/
Aslam, Amir, Singh, Jaipaul ORCID: 0000-0002-3200-3949 and Rajbhandari, Satyan 
(2016) An Observational Study on Lignocaine Infusion for Intractable Chronic Pain. 
Journal of Pain & Relief, 5 (255). ISSN 2167-0846  
It is advisable to refer to the publisher’s version if you intend to cite from the work.
http://dx.doi.org/10.4172/2167-0846.1000255
For more information about UCLan’s research in this area go to 
http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.
For information about Research generally at UCLan please go to 
http://www.uclan.ac.uk/research/ 
All outputs in CLoK are protected by Intellectual Property Rights law, including
Copyright law.  Copyright, IPR and Moral Rights for the works on this site are retained 
by the individual authors and/or other copyright owners. Terms and conditions for use 
of this material are defined in the http://clok.uclan.ac.uk/policies/
CLoK
Central Lancashire online Knowledge
www.clok.uclan.ac.uk
Aslam et al., J Pain Relief 2016, 5:4 
DOI: 10.4172/2167-0846.1000255
Research Article Open Access
Volume 5 • Issue 4  • 1000255J Pain Relief
ISSN: 2167-0846, JPAR an open access journal 
An Observational Study on Lignocaine Infusion for Intractable Chronic 
Pain
Amir Aslam1*, Jaipaul Singh2 and Satyan Rajbhandari2,3
1University of Calgary, Alberta, Canada
2School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, Lancashire, UK
3Department of Diabetology and Endocrinology, Lancashire Teaching Hospital NHS Trust, Chorley and South Ribble District General Hospital, Preston Road, 
Chorley, UK
*Corresponding author: Amir Aslam, Assistant Clinical Professor University of
Calgary, Family Physician at Eaton Centre Medical Clinic, 751 3rd Street, Suite
417, Calgary, Alberta, Canada, Email: AmirAslam@hotmail.com
Received April 19, 2016; Accepted July 05, 2016; Published July 08, 2016
Citation: Aslam A, Singh J, Rajbhandari S (2016) An Observational Study
on Lignocaine Infusion for Intractable Chronic Pain. J Pain Relief 5: 255.
doi:10.4172/2167-0846.1000255
Copyright: © 2016 Aslam A, et al. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
Keywords: Painful diabetic neuropathy; Chronic pain; Lignocaine
infusion
Introduction 
International association for the study of pain (IASP) defines 
neuropathic pain as “pain caused by a lesion or disease of the 
somatosensory nervous system”. Neuropathic pain is caused by direct 
injury or damage to, or pathological change in peripheral or central 
nervous system. In contrast, nociceptive pain is caused by direct injury 
or disease caused by tissue damage [1]. Chronic pain in general defines 
as pain last more than 3 to 6 months [2]. Chronic neuropathic pain is 
very common all over the world. It is estimated that almost 6% to 8% 
of the general population suffer from chronic neuropathic pain [3,4]. 
Painful diabetic neuropathic pain is the most common type of chronic 
neuropathic pain. 
Currently, about 380 million people worldwide are living with 
diabetes mellitus (DM) and it is estimated that this figure will rise 
up to 592 million in the year 2035 [5]. The prevalence of DM-related 
complications is also rising. Painful diabetic neuropathy (PDN) is a 
common complication of DM, affecting about 1/3rd of all patients with 
DM [6]. It is characterized by bilateral symmetrical distal neuropathic 
pain in lower extremities with varied symptoms from mild pins and 
needles, tingling sensation, shooting pain similar to electric shock, 
constant burning sensation with nocturnal exacerbation and contact 
hyper-sensitivity-allodynia [7]. Relentless pain and allodynia affect 
patients both physically and mentally and they both cause disturbance 
in sleep, low mood, impotence and social withdrawal. In some extreme 
cases the patient is unable to walk [8-10]. 
There are a number of trials of treatment of PDN which show 
some reduction of pain following treatment with either with tricyclic-
antidepressants amitriptyline [11], selective norepinephrine uptake 
inhibitor including duloxetine [11,12], venlafaxine [13], anticonvulsants 
including pregabalin [14-17], gabapentin [18,19], carbamazepine [20], 
topiramate [21,22] or in severe cases opioid [23]. A met analysis on 
efficacy on antidepressants and anticonvulsants in combination or alone 
showed up to 50% reduction in pain [24]. Trial with newer medication 
such as tapentadol which possesses dual mode of action, opioid agonists 
and norepinephrine uptake inhibitor show some improvement in 
painful diabetic neuropathy [25]. Apart from oral treatment, there are 
trials with some efficacy in treating PDN with topical agents including 
capsaicin [26] and also isosoribide mononitrate spray [27]. Despite 
of treatment advancement, chronic symptoms of PDN is challenging 
for clinicians and distressing for patient. Boulton et al followed up 39 
patients with painful diabetic neuropathy over the period of 4 years and 
found no significant difference in intensity of pain [28]. Another 5 year 
follow up study on PDN with conventional treatment reported a resolve 
of symptoms in only 23% patients [29]. 
A study on chronic neuropathic pain patients with combine 
conventional neuropathic treatment found up to 50% response rate only 
[30]. Despite of treatment advances and multiple drug regime up to 
50% of chronic neuropathic pain patients are resistant to conventional 
treatment. And some of these treatment resistant patients are in 
intractable pain. These challenging patients always been a challenge 
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for physicians. Lignocaine infusion has been reported with some 
satisfactory response on these challenging, conventional treatment and 
resistant patients [31-33]. 
Lignocaine is a sodium channel blocker. It was first synthesized by 
the Swedish chemist Nils Lofgren in 1943 [34]. Lignocaine is widely 
used as a local anaesthetic and for peripheral nerve blocks. It has 
been used intravenously for the treatment of arrhythmias and also 
found effective in chronic neuropathic pain [35] and chronic pain 
disorders [36,37] and is not associated with significant side effects 
[38]. Lignocaine metabolizes in the liver and its elimination half-life 
following an intravenous bolus injection is typically 1.5 to 2 hours. 
However, conditions with chronic liver disease and congestive heart 
failure may prolong its half-life.
The potential beneficial use of lignocaine infusion as a treatment 
in PDN was first evaluated by Kastrup [31]. There are several studies 
which reported pain relief in PDN [31-33]. Despite of rapid half-life, the 
duration of pain relief reported post lignocaine transfusion was up to 28 
days [31,32]. This could be due to the central de-sensitization effect of 
lignocaine along with peripheral action. The side effects in high doses of 
IV lignocaine can be sedation, hypotension and arrhythmia. However, 
studies found IV lignocaine infusion were very well tolerated and safe 
[31,32,38]. Lignocaine infusion is often preserved only for patients who 
have persistent excruciating pain and where other medications are not 
beneficial.
There are several pain assessment questionnaires available to assess 
the pain. This study used McGill short form (SF) questionnaire, which 
was developed by Melzack [39]. It is an easy, quick and an excellent 
tool to measure the quality of pain in three different aspects including 
sensory, affective and visual analogue score. It has been used as a 
measure of pain in variety of pain condition studies including painful 
diabetic neuropathy [32].
The aim of this study was to assess the efficacy of lignocaine infusion 
in patients with painful diabetic neuropathy (PDN group) compared to 
chronic pain patients (Non PDN group). 
Subjects and methods
PDN subjects with chronic refractory pain for (± SD) 6.5 ± 3.42 
years, not responded to standard oral and topical treatment were 
identified from Foot Clinic at Chorley District General Hospital 
(CDGH). Chronic pain subjects (non- PDN) with chronic refractory 
pain for (± SD) 7.75 ± 4.77 years, not responded to standard oral and 
topical treatment were referred for lignocaine infusion from Pain Clinic, 
Lancashire Hospitals NHS Trust. Both groups of patients already tried 
and were on multiple combination of pain medication without relief. 
Both groups of subjects attended individually and admitted to 
coronary care unit (CCU) as a day case for 3 hours and given lignocaine 
infusion 0.2% (2 mg/ml), 5 mg/kg body weight over 2 hours in coronary 
care unit of CDGH with throughout monitoring of electrocardiogram, 
blood pressure, pulse and oxygen saturations. A nurse administered 
McGill pain short form (SF) questionnaire before and after the infusion 
on each subjects. All patients recalled in “neuropathy pain clinic” in 6 
weeks’ time. All patients gave consent for participation. 
McGill SF consisted of 15 representative words from the sensory 
(n=11), affective (n=4) and visual analogue score (VAS). Each word 
descriptor was ranked by the patient on an intensity scale of 0, none; 
1, mild; 2, moderate; and 3, severe. Sensory score ranged from 0 to 33, 
affective score ranged from 0 to 12 and VAS range from 0 to maximum 
10 [39].
Statistical analysis
Data were analysed using Graph Pad software [40]. The continuous 
variable were normally distributed and expressed as means, ± standard 
deviation (SD), median and P value. The means of McGill pain score 
were analysed with paired Student’s t-test compared before and after 
lignocaine infusion. Categorical data were expressed as frequency 
distribution and percentage of subjects groups and p value. The 
categorical data of were analysed by 2 × 2 table using Fischer’s exact test. 
The boxplots created with descriptive statistics using Minitab statistical 
software (2013). The plot showed the median (dark band) along with 
minimum and maximum. The box represents the lower (Q1=25%) and 
upper (Q3=75%) quartile rang.
Results
Table 1 show the demographics and baseline characteristics of 
patients participated in the study. A total of 11 subjects participated in 
the study and completed the McGill SF questionnaire before and after 
the lignocaine infusion. The mean age (± SD) of subject was 52 ± 13.96 
years. There were total of 4 males (36%) with mean age (± SD) 58.7 ± 
15 years and 7 females (64%) with mean age (± SD) of 49 ± 13 years. 
The mean duration of chronic pain (± SD) was 7.09 ± 4.37 years. The 
mean sensory score before lignocaine infusion was (± SD) 20.14 ± 7.16 
compared to mean sensory score after lignocaine infusion was (± SD) 
16.5 ± 9.52. There was significant reduction of sensory pain score after 
lignocaine infusion (p<0.05). The mean affective score before lignocaine 
infusion was (± SD) 5.5 ± 3.09 compared to mean affective score after 
lignocaine infusion was (± SD) 4.0 ± 3.13. There was a significant 
reduction of affective pain score after lignocaine infusion (p<0.05). The 
mean visual analogue score (VAS) before lignocaine infusion was (± 
SD) 7.72 ± 1.75 compared to mean VAS score after lignocaine infusion 
was (± SD) 6.13 ± 2.53. There was a reduction of VAS pain score after 
lignocaine infusion, however the data were statistically not significant 
(p=0.053) (Figure 1). The box plot analysis in Figure 1 shows the McGill 
pain score in all 3 sub-categories including sensory score, affective score 
and visual analogue scores (VAS) which were part of McGill SF pain 
score either before (A) or after (B) the lignocaine infusion in all subjects 
with chronic pain. Before lignocaine infusion, the sensory score mean 
was 20.4 ± 7.16 SD (median 20) compared to sensory score mean after 
lignocaine infusion was 16.5 ± 9.52 SD (median 17.5) (p<0.014). Before 
lignocaine infusion, the affective score mean was 5.5 ± 3.09 SD (median 
5) compared to affective score mean after lignocaine infusion was 4.0 ± 
3.13 SD (median 3.0) (P< 0.013). Before lignocaine infusion, the VAS 
score mean was 7.72 ± 1.75 SD (median 8) compared to VAS score mean 
after lignocaine infusion was 6.13 ± 2.53 SD (median 7) (p=0.053). The 
plot also shows the median score (dark band) along with minimum and 
maximum score. The box represents the lower (Q1=25%) and upper 
(Q3=75%) quartile range of score. All male participants had painful 
diabetic neuropathy (PDN group) as a cause of pain and all female 
participants had non PDN cause of chronic pain. The ages in both 
gender- ages and groups were similarly distributed (p>0.05). The mean 
duration of pain (± SD) in PDN group was 6.5 ± 3.42 years compared 
to 7.75 ± 4.77 years in Non PDN group. The duration of pain in both 
groups were similarly distributed (p>0.05). Both groups had tried a 
combination of medications including antidepressants, antiepileptic 
medications, and opioid and moreover, they were on combination of 
medications with unsatisfactory response. 
The results also show 33% reduction of visual analogue pain 
score after lignocaine infusion in PDN group compared to 11% 
reduction of visual analogue pain score in non-PDN group. The data 
were statistically significant (p<0.05) (Figure 2). Similarly, there was 
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a significant (p<0.05) reduction of affective pain score, 41% after 
lignocaine infusion in PDN group compared to 21% in non-PDN group 
(Figure 3). In contrast, the sensory pain score reduction after lignocaine 
infusion was 23% in PDN group compared to 17% in non-PDN group. 
These data were statistically not significant (p>0.05) (Figure 4).
All 11 patients had no reported adverse effects and their 
observations including electrocardiograms, pulse, blood pressure and 
oxygen saturation were in normal limits throughout the lignocaine 
infusion. In this and subsequent figures, PDN (B) = Painful diabetic 
neuropathy group score before lignocaine infusion
PDN (A)=Painful diabetic neuropathy group score after 
lignocaine infusion; Non-PDN (B)=Non-painful diabetic neuropathy 
group score before lignocaine infusion; Non-PDN (A)=Non- 
painful diabetic neuropathy group score after lignocaine infusion; 
VAS=Visual analogue score
The box plot analysis in Figure 2 shows the visual analogue score 
(VAS) which was part of McGill SF pain score either before (A) or after 
(B) the lignocaine infusion in PDN group and non-PDN group. Before 
lignocaine infusion, the VAS mean score was 8.87 ± 1.03 SD (median 
9.0) compared to VAS mean score after lignocaine infusion which was 
5.87 ± 3.06 SD (median 5.75) (33% pain reduction). In Non-PDN group 
(n=7), before lignocaine infusion, the mean VAS score was 7.07 ± 1.7 













Before Lignocaine infusion After Lignocaine infusion
VAS Sensory Affective VAS Sensory Affective
1 79 Male Yes 11 Amitriptyline, Imipramine, 
Carbamazepine, Capsaicin 
cream, Tramadol, 
Pregabalin, Mexiletine, GTN 





7.5 8 1 3.5 3 3.5
2 60 Male Yes 3 Pregabalin, Amitriptyline 
Duloxetine, Clonazepam, 






Durogesic patch,  
Oramorph PRN.
9 32 7 9 29 9
3 44 Male Yes 5 Gabapentin, Butrans 





9 12 6 3 4 3
4 52 Male Yes 7 Pregabalin, Gabapentin, 
topical Capsaicin, 






10 22 3 8 21 8
5 41 Female No Back Pain 5 Carbamazepine, 
Duloxetine, Amitriptyline, 
Pregabalin, Ropinerole. SI 
joint injections, Facet joint 







8 30 9 8 29 8
6 66 Female No 
Fibromyalgia






4 20 5 3 11 3





7 19 4 3 7 3
8 59  Female No 
Angiolipoma
7 Gabapentin, Cocodamol 
30/500, SI joint injection, 






9 18 4 6 15 6
9 26 Female No 
Fibromyalgia







6 16 3 8 18 8
10 45 Female No 
Demyelination
6 Gabapentin, Pregabalin, 
Nabilone, Ketamine, 
Butranspatch, codeine, 
Capsaicin cream, Lidocaine 
patch, Fentanyl patch, 
Duloxetine, Topiramate, 
Carbamazepine, TENS
Amitriptyline 50 mg 
Codeine 60 mg at 
night 
6.5 21.5 6.5 7 17.5 7
11 54 Female No Stump 
pain
4 Paracetamol , Oramorph 









9 26 12 9 27 9
Table 1: Demographics and baseline characteristics of patients participated in the study.
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7) (11% pain reduction) after lignocaine infusion. The pain reduction 
of PDN group compared to Non-PDN group was statically significant 
(p<0.0015). 
The box plot analysis in Figure 3 shows the affective score of McGill 
pain SF score either before (B) or after (A) the lignocaine infusion in 
PDN group and non-PDN group. The results show that in the in PDN 
group, the affective mean score was 4.25 ± 2.75 SD (median 4.5) before 
lignocaine infusion compared to affective mean score of 2.50 ± 3.11 SD 
(median 1.5) (41% pain reduction) after lignocaine infusion. In Non-
PDN group (n=7), before lignocaine infusion, the mean affective score 
was 6.17 ± 3.54 SD (median 4.5) compared to affective mean score 4.83 
± 3.31 SD (median 3.5) (21% pain reduction) after lignocaine infusion 
was the pain reduction of PDN group compared to Non-PDN group 
was statistically significant (p<0.0036). 
The box plot analysis in Figure 4 shows the sensory score of McGill 
pain SF score either before (B) or after (A) lignocaine infusion in 
PDN group and non-PDN group. In PDN group, the sensory mean 
score was 18.5 ± 10.75 SD (median 17.0) before lignocaine infusion 
compared to sensory mean score 14.25 ± 12.84 SD (median 12.5) 
(23% pain reduction) after lignocaine infusion. In Non-PDN group, 
before lignocaine infusion, the mean sensory score was 21.50 ± 5.36 
SD (median 19.5) compared to sensory mean score 17.83 ± 8.73 SD 
(median 16.5) (17% pain reduction) after lignocaine infusion. The 
pain reduction of PDN group compared to Non-PDN group was not 
statically significant (p=0.3769). 
The box plot analysis in Figure 5 shows the 95% pain relief after 
lignocaine infusion in responder (1) and 5% in non-responder (2) of 
diabetic patients. The pain reduction in responder compare to non-
responder was statistically significant (p<0.0001). 
In responder group, the duration of diabetes mean score was 15.5 
years ± 0.71 SD, HbA1c mean score was 64 mmol/mol ± 15.5 SD and 
Age means score was 61.5 years ± 24.75 SD compared to 10 years ± 2.83 
SD, 66.5 mmol/mol ± 3.5 SD and 56 years ± 5.66 SD in non-responder 
group respectively. The data for duration of diabetes, HbA1c and Age 
in responder group compared to non-responder were not statically 
significant (p<0.116, p<0.84 and p<0.79 respectively). 
Discussion 
Painful diabetic neuropathy (PDN) is one of the common 
complications of diabetes mellitus (DM). About 1/3 of all patients with 
DM suffer from diabetic neuropathic pain [6] and moreover, it has a 
huge impact on the quality of life (QoL) of the person [8-10]. There are 
Figure 1:  Box plot showing sensory score, affective score and visual 
analogue score (VAS) compared before (B) and after (A) lignocaine infusion 
in chronic pain subjects. Data are mean ±  SD; n=11, * p<0.05 for sensory 
















McGill SF pain scores before (B) and after (A) lignocaine infusion
Sensory Score Affective Score VAS Score  
Figure 2:  Box plot showing visual analogue score either before (B) or after 
(A) lidocaine infusion in PDN and non-PDN groups. Data are mean ± SD; 

















Visual Analogue Score before (B) and after (A) lignocaine infsuion 
Figure 3:  Box plot showing affective score either before (B) or after (A) 
lidocaine infusion. Data are mean ± SD; n=11, with 4 for PDN group and 7 
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Figure 4: Box plot showing sensory score either before (B) or after (A) 
lidocaine infusion. Data are mean ±  SD; n=11, with n=4 for PDN group and 
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several trials which have reported some benefit in the improvement of 
symptoms of PDN with various antidepressants, anticonvulsants, opioid 
and topical medications [11-27]. The follow up studies reported that 
only 23% patients had satisfactory improvement of symptoms of PDN 
after conventional treatment [28,29]. Most of the patients tolerate the 
residual pain and live with it, however there are reports of severe PDN 
with constant unrelenting neuropathic pain, disturbance of sleep and 
even unable to walk due to severity of pain [8-10]. Lignocaine infusion 
has been used as a treatment when other conventional treatments 
were not helpful in various chronic challenging painful conditions 
including chronic pain syndrome [36,37], chronic neuropathic pain 
[35] including painful diabetic neuropathy [31-33]. 
The present data have shown reduction in all 3 domains of pain 
scores of McGill SF pain questionnaire including visual analogue score 
of 33%, affective scores of 41% and sensory scores of 23% in PDN group 
after lignocaine infusion compared to 11%, 21% and 17%, respectively 
in non-PDN group. The data were statistically significant for VAS and 
affective scores. However, the data were not statistically significant for 
sensory scores. This could be due to the statistically significant response 
of lignocaine infusion on sensory scores in both groups of patients 
(Figure 1). 
Comparison with existing data
The data from this study have clearly shown a significant reduction 
of McGill SF pain scores- affective score and visual analogue score after 
lignocaine infusion in patients with PDN compares to those patients 
with chronic pain (non-PDN). These results are consistent with those 
obtained by Viola et al. [32] and Kastrup et al. [31] who demonstrated 
significant reduction of both affective scores and visual analogue scores 
after lignocaine infusion. The present study measured effectiveness 
of lignocaine infusion as a treatment on PDN patients compared to 
chronic pain patients with other causes. In contrast, in their studies 
Viola et al. [32] and Kastrup et al. [31] measured the effectiveness of 
lignocaine infusion compared with saline infusion in patients with 
PDN. In our study, the reduction of McGill SF sensory pain score was 
23% in PDN group compared to 17% in non-PDN group. Despite of 
quarter of reduction of sensory pain score in PDN group, the data were 
not statistically significant. In contrast Viola et al. [32] and Kastrup et 
al. [31] showed significant reduction of McGill sensory pain score. This 
discrepancy in the results could be due to the fact that the lignocaine 
Figure 5: Box plot showing pain relief (PR) in percentage, duration of 
diabetes in years, HbA1c in mmol/mol and Age in years either responder (1) 
or non-responder (2) of lignocaine infusion. Data are mean ± SD; n=4, with 
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infusion responded almost to the same level in both PDN and non-PDN 
groups. Therefore, the comparison difference was not significant. The 
present study was similar to that of Viola et al study [32] where all the 
patients participated with intractable pain and who failed to respond to 
or intolerant to conventional treatment. It is particularly noteworthy, 
that in this and the studies done by Viola et al study [32] and Kastrup 
et al. study [31], no participants had any adverse effects with lignocaine 
infusion of 5 mg/kg bodyweight. This observation clearly suggests that 
it is quite safe to use this dose of lidocaine to treat PDN. However, there 
is a report [41] which reported that lignocaine infusion had marked 
adverse effects resulting in hypotension and arrhythmia. The study 
is related to fibromyalgia patients and lignocaine infusion was given 
consecutively for 6 days. Also, the dose was increased incrementally 
every day to maximum of 5 mg/kg bodyweight plus 150 mg or total 
maximum 550 mg [41]. 
There are several studies reporting significant reduction of 
pain after lignocaine infusion in PDN and a variety of non-PDN 
conditions including fibromyalgia [41], headache [42], back pain [43], 
trigeminal neuralgia [44] and chronic pain syndrome [36,37]. Like 
previous investigations, the present study also showed a beneficial 
effect of lignocaine infusion to treat both PDN and non-PDN group. 
However, in patients with PDN lignocaine infusion was statistically 
more effective than other causes of chronic pain. PDN pathogenesis 
involves peripheral and central sensitization with neural plasticity 
[45]. The half–life of Lignocaine infusion is only 2 hours, however the 
effect of analgesia reported up to 28 days. This observation suggests 
that lignocaine infusion may affect not only peripheral, but perhaps 
central neural plasticity as well. This may be due to the central effect of 
lignocaine where it was more effective in PDN group. 
Strength and Limitation of the study
The study population was well defined for both groups and 
completed with minimal selection bias as the participations from both 
PDN and non-PDN groups were referred from Foot Clinic or Pain 
Clinic for lignocaine infusion, respectively. Moreover, both groups of 
participants responded 100% in filling McGill SF pain questionnaires. 
Both groups were similar in age, however all participants in PDN group 
were males and non-PDN group were females. Recall bias could exist 
when participants filling out questionnaire. However, most questions 
from McGill SF questionnaire were based on current or recent physical 
and mental wellbeing of person, hence recall bias were minimal. The 
results also show that lignocaine infusion had no significant effect on the 
ECG, BP, pulse rate or oxygen saturation in the both groups of patients. 
This was the observational study and all patients were well aware that 
they were having treatment with lignocaine infusion, therefore possible 
placebo effect cannot be ruled out. Also the sample size was very small 
only 4 in PDN group and 7 in non PDN group. Further randomize 
control trial with large sample needed to see the true results. 
Conclusion
Overall, the study has shown that lignocaine infusion is both 
effective and safe in reducing the chronic intractable pain when 
conventional treatment are intolerable or not helpful in PDN and 
non-PDN patients. It is more effective in PDN patients compared to 
other causes of chronic pain. There is a need for randomize control 
trial to see the effect of lignocaine infusion especially in PDN. Chronic 
neuropathic pain including PDN causes modulation of pain at spinal 
level and plasticity of brain, as a result it’s more difficult to treat the 
refractory pain [45]. Perhaps we may need to consider,  lignocaine 
infusion in early stage when conventional treatments are not helpful. 
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